Bristol Myers Squibb's Portfolio Transformation

Bristol Myers Squibb (BMY) reported first-quarter revenue of $11.49 billion, a 3% increase year-over-year. The company's growth portfolio achieved a 12% increase, reaching $6.2 billion in revenue, accounting for over 54% of total revenue, demonstrating its potential for generational change. However, Revlimid (lenalidomide) revenue declined by 63% to $349 million due to patent expiration and generic competition, hindering growth. Cobenfy (xanomeline-trospium), a new treatment for schizophrenia, generated $56 million in revenue, showing steady progress. However, to fully overcome the declining performance of the legacy portfolio due to patent expiration, accelerating the performance of new drugs is crucial.

Biogen's Successful Performance Recovery Driven by New Drugs

Biogen (BIIB) achieved strong first-quarter results, exceeding market expectations, signaling a turnaround. Global revenue for Leqembi (lecanemab), an Alzheimer's disease treatment, increased by 74% year-over-year to $168 million, driving growth. Skyclarys (omaveloxolone), a treatment for Friedreich's ataxia, also showed strong performance with a 22% increase to $151 million. These results demonstrate that Biogen, which had struggled with patent expirations of blockbuster drugs, has secured new growth drivers focused on targeted therapies.

Regeneron's Patent Challenges and Uncertain Performance Outlook

Regeneron Pharmaceuticals (REGN) reported total revenue of $3.6 billion in the first quarter, a 19% increase year-over-year. However, increased competition in key products is causing concern among investors. Revenue for the Eylea (aflibercept) franchise in the United States decreased by 10% to $941 million. Although the high-dose formulation, Eylea HD, grew by 52% to $468 million, it was not enough to offset the pressure from Roche's Vabysmo (faricimab) and the launch of biosimilars. Dupixent (dupilumab), a treatment for atopic dermatitis, generated global revenue of $4.9 billion, a 33% increase, providing support. However, regulatory risks, including price negotiations with the U.S. government, are clouding the future outlook.

Strategic Restructuring in Response to Intensified Market Competition

The recent earnings announcements indicate a rapid reshaping of the competitive landscape in the neurological and ophthalmological therapeutics market. Biogen's Leqembi has solidified its position in the Alzheimer's disease treatment market, demonstrating a strong first-mover advantage despite the launch of Eli Lilly's Kisunla (donanemab). In the ophthalmology sector, Regeneron's monopoly is breaking down, and fierce competition with Vabysmo is intensifying, leading to increased pressure on price reductions and marketing costs. For companies to ensure sustainable growth after patent expiration, securing Phase 3 clinical data for next-generation drugs and obtaining rapid insurance coverage are more important than ever.